規格 | 目錄價格 | 上海 | 安徽 | 武漢 | 成都 | 北方 | 深圳 | 會員價格 | 數量 |
---|---|---|---|---|---|---|---|---|---|
100mg | ¥ ?????? | > 10 | > 10 | -- | -- | 2 | -- | ¥ ?????? | - + |
250mg | ¥ ē????? | > 10 | > 10 | -- | -- | -- | -- | ¥ ē????? | - + |
1g | ¥ ?????? | 10 | > 10 | -- | -- | -- | -- | ¥ ?????? | - + |
5g | ¥ ēē????? | 2 | 9 | -- | -- | -- | -- | ¥ ēē????? | - + |
10g | 請詢價 | -- | -- | -- | -- | -- | -- | -- | - + |
25g | 請詢價 | -- | -- | -- | -- | -- | -- | -- | - + |
100g | 請詢價 | -- | -- | -- | -- | -- | -- | -- | - + |
產品編號
1187584
CAS 號
2010-15-3
中文名稱
3-苯基-2-硫代氧雜咪唑啉-4-酮
MDL 號
MFCD00027413
分子量
192.23762
存儲條件
2-8°C
網頁展示純度為入庫指導純度值,各批次間存在一定差異,實際純度以收貨為準
熔點
257 °C
沸點
292.1±23.0 °C at 760 mmHg
閃點
旋光
描述
TPSA
32.34
LogP
0.9077
H_Acceptors
2
H_Donors
1
Rotatable_Bonds
1
[1]. Alfredo Berruti, et al. Enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Dec 20;367(25):2448; author reply 2448-9.
[2]. David End, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2013 May 1;73(9):2926.
[3]. Fernand Labrie, et al. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology. J Steroid Biochem Mol Biol. 2015 Jan:145:144-56.
[4]. I Ouzaid, et al. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come]. Prog Urol. 2013 Jan;23(1):1-7.
[5]. Julie N Graff, et al. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology. 2013 Feb;81(2):381-3.
警示圖
警示詞
Danger
危險申明
H301-H311-H331
警告申明
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361-P363-P405-P501
GHS 編碼
GHS06
危險類別
6.1
UN 編碼
2811
包裝等級
Ⅲ
展開更多
現貨供應
專業護航
售后無憂
品質保障
無需湊單